-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MER-3101 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MER-3101 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MER-3101 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MER-3001 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MER-3001 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MER-3001 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVCoV-2 in Middle East Respiratory Syndrome (MERS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVCoV-2 in Middle East Respiratory Syndrome (MERS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NVCoV-2 in Middle East Respiratory Syndrome (MERS) Drug Details:...
-
Product Insights
Tyrosine Protein Kinase Mer – Drugs In Development, 2023
Global Markets Direct’s Tyrosine Protein Kinase Mer provides in depth analysis on Tyrosine Protein Kinase Mer targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase...
-
Product Insights
Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2023’, provides an overview of the Middle East Respiratory Syndrome (MERS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTI-03 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTI-03 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LTI-03 in Idiopathic Pulmonary Fibrosis Drug Details: LTI-03 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRX-2843 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRX-2843 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRX-2843 in Non-Small Cell Lung Cancer Drug Details: MRX-2843 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MLT-103 in Influenza A Virus, H1N1 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MLT-103 in Influenza A Virus, H1N1 Subtype Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MLT-103 in Influenza A Virus, H1N1 Subtype Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adrixetinib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adrixetinib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adrixetinib in Non-Small Cell Lung Cancer Drug Details: Adrixetinib (Q-702)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adrixetinib in Hematological Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adrixetinib in Hematological Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adrixetinib in Hematological Tumor Drug Details: Adrixetinib (Q-702) is under development for...